{"entity":{"id":"nct04624204","kind":"trial","name":"Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-","aka":[],"tldr":"A phase 3 trial of Pembrolizumab, Olaparib in small-cell lung cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.","summary":"Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013) is a phase 3 interventional study registered as NCT04624204 by Merck Sharp & Dohme LLC, with 672 participants planned, started 2020-12-08 and due to reach its primary completion in 2027-10-28. Interventions recorded: Pembrolizumab 200 mg, Pembrolizumab 400 mg, Pembrolizumab placebo (saline), Pembrolizumab placebo (saline), Olaparib 300 mg BID. Conditions listed: Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04624204","url":"https://clinicaltrials.gov/study/NCT04624204"}],"tags":["ctgov-ingest"],"related":[],"cancers":["sclc","limited-stage-sclc"],"sections":[],"technologies":["checkpoint-inhibitor","parp-inhibitor"],"targets":[],"drugs":["pembrolizumab","olaparib"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04624204","phase":"3","setting":"A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib (MK-7339), Compared to Concurrent Chemoradiation Therapy Alone in Participants With Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC)","sponsor":"Merck Sharp & Dohme LLC","participation":[{"nct":"NCT04624204","source":"https://clinicaltrials.gov/study/NCT04624204","fetchedAt":"2026-10-07T16:53:23.898Z","studySha256":"089e98125bc87e50299e71f92862915c08a80f2d2e39b9fc7b105f38d23dd87f","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-09-24","leadSponsor":"Merck Sharp & Dohme LLC","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":672,"enrolmentType":"ESTIMATED","siteCount":187,"recruitingSiteCount":0,"countries":["Australia","Belgium","Bulgaria","Canada","China","Estonia","France","Greece","Hungary","Israel","Italy","Japan","Lithuania","Mexico","Portugal","Romania","Russia","Serbia","South Africa","South Korea","Spain","Turkey (Türkiye)","Ukraine","United Kingdom","United States"]}],"started":"2020-12-08","startedType":"actual","enrolled":672,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04624204/","neighbours":{"cancer":[{"id":"limited-stage-sclc","kind":"cancer","name":"Limited-stage small-cell lung cancer","route":"/cancers/limited-stage-sclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/"}],"drug":[{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}